These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 2360840)

  • 1. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988.
    Hörnsten P; Keisu M; Wiholm BE
    Arch Dermatol; 1990 Jul; 126(7):919-22. PubMed ID: 2360840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Agranulocytosis induced by dapsone prescribed for dermatitis herpetiformis].
    Machet L; Callens A; Mercier E; Gargot S; Lorette G; Vaillant L
    Ann Dermatol Venereol; 1996; 123(5):328-30. PubMed ID: 8761086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agranulocytosis during dapsone administration.
    Ten Broeke JE; Cunningham LD
    Dermatologica; 1973; 146(1):21-4. PubMed ID: 4694139
    [No Abstract]   [Full Text] [Related]  

  • 4. Proliferation of IgD kappa plasma cells after agranulocytosis induced by dapsone.
    Lahuerta-Palacios JJ; Gomez-Pedraja JF; Montalban MA; Shandas GJ; Gomez-Salazar MD
    Br Med J (Clin Res Ed); 1985 Jan; 290(6464):282-3. PubMed ID: 3917786
    [No Abstract]   [Full Text] [Related]  

  • 5. The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis.
    Prussick R; Ali MA; Rosenthal D; Guyatt G
    Arch Dermatol; 1992 Feb; 128(2):210-3. PubMed ID: 1739299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic use of dapsone in dermatitis herpetiformis (Duhring) and in certain inflammatory skin diseases].
    Révész K; Schneider I
    Orv Hetil; 1995 Jan; 136(2):59-62. PubMed ID: 7862431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapsone and severe hypoalbuminaemia in dermatitis herpetiformis.
    Cowan RE; Wright JT
    Br J Dermatol; 1981 Feb; 104(2):201-4. PubMed ID: 7213552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients.
    Coleman MD; Rhodes LE; Scott AK; Verbov JL; Friedmann PS; Breckenridge AM; Park BK
    Br J Clin Pharmacol; 1992 Sep; 34(3):244-9. PubMed ID: 1389948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agranulocytosis--a case report.
    Rahman J; Chowdhury SA; Wajed J
    Bangladesh Med Res Counc Bull; 2000 Aug; 26(2):65-8. PubMed ID: 11508074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention.
    Coleman MD
    Toxicology; 2001 Apr; 162(1):53-60. PubMed ID: 11311458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and prevalence of dermatitis herpetiformis in a country in central Sweden, with comments on the course of the disease and IgA deposits as diagnostic criterion.
    Moi H
    Acta Derm Venereol; 1984; 64(2):144-50. PubMed ID: 6203303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid.
    McFadden JP; Leonard JN; Powles AV; Rutman AJ; Fry L
    Br J Dermatol; 1989 Dec; 121(6):759-62. PubMed ID: 2692691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylator phenotype, minimal maintenance dose and haemolytic effect of dapsone in dermatitis herpetiformis.
    Förström L; Mattila MJ; Mustakallio KK
    Ann Clin Res; 1974 Oct; 6(5):308-10. PubMed ID: 4447343
    [No Abstract]   [Full Text] [Related]  

  • 14. Dapsone-induced peripheral neuropathy.
    Epstein FW; Bohm M
    Arch Dermatol; 1976 Dec; 112(12):1761-2. PubMed ID: 188385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manic depression induced by dapsone in patient with dermatitis herpetiformis.
    Gawkrodger D
    BMJ; 1989 Sep; 299(6703):860. PubMed ID: 2510873
    [No Abstract]   [Full Text] [Related]  

  • 16. [Polyneuropathy in Duhring dermatitis herpetiformis].
    Dillmann U; Krämer G; Goebel HH
    Nervenarzt; 1991 Aug; 62(8):516-8. PubMed ID: 1944718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurologic symptoms posing as dapsone-induced polyneuropathy in two patients with dermatitis herpetiformis.
    Fernandez-Obregon AC; Forconi RJ
    Cutis; 1988 May; 41(5):347-50. PubMed ID: 2836133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Sulfoxone (Diasone) sodium for dermatitis herpetiformis" by Cornbleet, December 1951. Commentary: Sulfoxone (Diasone) in the treatment of dermatitis herpetiformis.
    Katz SI
    Arch Dermatol; 1982 Oct; 118(10):805-12. PubMed ID: 6753759
    [No Abstract]   [Full Text] [Related]  

  • 19. Possible dapsone-induced peripheral neuropathy in dermatitis herpetiformis.
    du Vivier A; Fowler T
    Proc R Soc Med; 1974 Jun; 67(6 Pt 1):439-40. PubMed ID: 4369028
    [No Abstract]   [Full Text] [Related]  

  • 20. Gall-bladder perforation after long-term dapsone therapy.
    Choy AM; Lang CC
    J Intern Med; 1990 Oct; 228(4):409-10. PubMed ID: 2266352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.